Prostatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics. With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally. Gerald L. Andriole, Jr., MD, was most recently Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University.

Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania.

He completed urology residency at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Professor Andriole has over 35 years of consistent contributions in caring for men with prostate cancer and in prostate cancer prevention, screening and treatment research.

He has contributed more than 450 peer-reviewed publications and has served on the editorial boards of several prestigious medical journals. He has been Chairman of the Prostate Committee of the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; Chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and Chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial.